BMRN - BIOMARIN PHARMACEUTICAL INC

QQQ $ 480.91 $ -0.39 (-0.08 %)

DIA $ 408.42 $ -0.47 (-0.11 %)

SPY $ 559.03 $ -0.13 (-0.02 %)

TLT $ 98.59 $ 0.29 (0.3 %)

GLD $ 232.27 $ -1.45 (-0.62 %)

Previous Close

$ 92.76

Open

$ 93.88

Bid

$ 94.12 x 100

Ask

$ 94.22 x 200

Day's Range

$ 93.01 - $ 94.81

52 Week Range

$ 73.68 - $ 99.56

Volume

1,550,168

Average Volume

Market Cap

18.6B

Beta (5Y Monthly)

$ 0.66

PE Ratio (TTM)

$ 72.49

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-05-2024	06-30-2024	10-Q
2	04-26-2024	03-31-2024	10-Q
3	02-26-2024	12-31-2023	10-K
4	11-02-2023	09-30-2023	10-Q
5	08-02-2023	06-30-2023	10-Q
6	04-28-2023	03-31-2023	10-Q
7	02-27-2023	12-31-2022	10-K
8	10-28-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	04-29-2022	03-31-2022	10-Q
11	02-25-2022	12-31-2021	10-K
12	10-29-2021	09-30-2021	10-Q
13	07-30-2021	06-30-2021	10-Q
14	04-30-2021	03-31-2021	10-Q
15	02-26-2021	12-31-2020	10-K
16	11-06-2020	09-30-2020	10-Q
17	08-05-2020	06-30-2020	10-Q
18	05-01-2020	03-31-2020	10-Q
19	02-27-2020	12-31-2019	10-K
20	10-29-2019	09-30-2019	10-Q
21	08-02-2019	06-30-2019	10-Q
22	04-29-2019	03-31-2019	10-Q
23	02-28-2019	12-31-2018	10-K
24	10-26-2018	09-30-2018	10-Q
25	08-03-2018	06-30-2018	10-Q
26	04-27-2018	03-31-2018	10-Q
27	02-26-2018	12-31-2017	10-K
28	10-31-2017	09-30-2017	10-Q
29	08-02-2017	06-30-2017	10-Q
30	05-04-2017	03-31-2017	10-Q
31	02-27-2017	12-31-2016	10-K
32	11-03-2016	09-30-2016	10-Q
33	08-08-2016	06-30-2016	10-Q
34	05-02-2016	03-31-2016	10-Q
35	02-29-2016	12-31-2015	10-K
36	11-02-2015	09-30-2015	10-Q
37	08-05-2015	06-30-2015	10-Q
38	05-05-2015	03-31-2015	10-Q
39	03-02-2015	12-31-2014	10-K
40	10-28-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Beyond The Numbers: 11 Analysts Discuss Bi...
08/20/2024 18:00:14

palo-alto-networks-to-rally-more-than-16-here-are-10-top-analyst-forecasts-for-tuesday

Palo Alto Networks To Rally More Than 16%?...
08/20/2024 11:53:39

Bernstein Upgrades Biomarin Pharmaceutical...
08/20/2024 09:37:54

Bernstein analyst William Pickering upgrades Biomarin Pharmaceutical (NASDAQ:BMRN) from Market Perform to Outperform and rai...

1000-invested-in-biomarin-pharmaceutical-20-years-ago-would-be-worth-this-much-today

$1000 Invested In Biomarin Pharmaceutical ...
08/07/2024 17:30:19

rare-disease-focused-biomarin-narrows-sales-focus-cuts-cost-for-hemophilia-a-gene-therapy-lifts-annual-guidance

Rare Disease-Focused BioMarin Narrows Sale...
08/06/2024 19:06:26

BioMarin Pharmaceutical shifts focus to commercial operations for Roctavian in the U.S., Germany, and Italy. Projected cost red...

TD Cowen Maintains Buy on Biomarin Pharmac...
08/06/2024 16:43:16

TD Cowen analyst Phil Nadeau maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $12...

Scotiabank Maintains Sector Perform on Bio...
08/06/2024 16:40:33

Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and raises the price ...

yum-china-posts-upbeat-earnings-joins-clear-secure-tg-therapeutics-bioventus-and-other-big-stocks-moving-higher-on-tuesday

Yum China Posts Upbeat Earnings, Joins Cle...
08/06/2024 15:47:18

RBC Capital Reiterates Sector Perform on B...
08/06/2024 13:11:15

RBC Capital analyst Luca Issi reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and maintains $100 pric...

Barclays Maintains Overweight on Biomarin ...
08/06/2024 13:02:07

Barclays analyst Gena Wang maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target fro...

biomarin-pharmaceutical-analysts-boost-their-forecasts-following-better-than-expected-q2-results

Biomarin Pharmaceutical Analysts Boost The...
08/06/2024 12:36:48

Evercore ISI Group Maintains Outperform on...
08/06/2024 12:30:20

Evercore ISI Group analyst Cory Kasimov maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the pri...

Stifel Maintains Buy on Biomarin Pharmaceu...
08/06/2024 11:25:19

Stifel analyst Paul Matteis maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $108...

Biomarin Pharmaceutical Q2 2024 Adj EPS $0...
08/05/2024 20:13:13

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate ...

BioMarin To Reduce Operating Expenses To A...
08/05/2024 20:02:12

Cantor Fitzgerald Reiterates Overweight on...
08/05/2024 13:49:58

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $11...

Canaccord Genuity Maintains Hold on Biomar...
07/25/2024 13:07:52

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold and maintains $89 price t...

U.S. FDA Approves BioMarin's BRINEURA For ...
07/24/2024 20:25:39

Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show SymptomsSAN RAFAEL, Calif.,...

A Glimpse Into The Expert Outlook On Bioma...
07/22/2024 17:00:44

Cantor Fitzgerald Reiterates Overweight on...
07/22/2024 15:22:34

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $11...

6 Gene Therapy M&A Targets On The Radar
03/27/2019 16:45:40